COMPANY RESEARCHNIS published original research on a commercial small-molecule MicroED workflow and adopted the unified TrueCourse brand with Proteos in 2026.
Amendment filing date; first sale on 2024-09-04. Cumulative securities sold in the same offering, not new financing in 2025 or all-time company financing.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
The current website includes a paper on a commercial small-molecule MicroED service workflow that reports handling client samples during the study period.
The current website timeline confirms NIS was founded in 2007, acquired Proteos in 2025, and adopted a unified brand in 2026.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| MicroED / 3D ED service capabilities | Determined by the submitted sample and research question · Not applicable; service capability | Services / platform | Not applicable; not a human clinical program |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
This article explores how Microcrystal Electron Diffraction (MicroED) is set to revolutionize drug polymorph research workflows. Drawing upon recent news, official websites, and LinkedIn updates from Crystal Pharmatech and Eldico, it clearly distinguishes between verified facts, industry viewpoints, and information pending verification.
Direct Electron lists a REyes webinar for November 10, 2026, at noon Eastern Time. It will discuss diffraction-guided screening, automated acquisition and structure solution, including integration with SerialEM.
Crystal Pharmatech’s November 4 announcement confirms ED-1 service in Suzhou. Its service page describes integration with solid-form screening for small crystals and pharmaceutical solid forms.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.